Viatris Sells Biocon Biologics Stake for $815 Million, Reenters Biosimilars Market

Viatris Sells Biocon Biologics Stake for $815 Million, Reenters Biosimilars Market

On December 6, 2025, Viatris Inc. announced the sale of its equity stake in Biocon Biologics Limited to Biocon Limited for a total consideration of $815 million. This strategic move includes $400 million in cash and $415 million in newly issued equity shares of Biocon Limited. The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions.

Details of the Transaction

Under the definitive agreements, Viatris will divest its convertible preferred equity in Biocon Biologics. The newly issued equity shares of Biocon Limited will be listed and traded on the National Stock Exchange of India, with a six-month lock-up period. Additionally, the agreement accelerates the expiration of biosimilars non-compete restrictions previously placed on Viatris in 2022. These restrictions will expire immediately upon closing for all ex-U.S. markets and in November 2026 for U.S. markets.

Strategic Implications

Scott A. Smith, CEO of Viatris, stated that monetizing the equity stake in Biocon Biologics and regaining access to the global biosimilars market provides significant optionality as the company continues to build a portfolio of generics, established brands, and innovative brands that can contribute to future growth.

Market Reaction

Following the announcement, Viatris’ stock (ticker: VTRS) experienced a positive market response. As of August 14, 2026, the stock closed at $16.23, reflecting a 2.06% increase from the previous close. This uptick indicates investor confidence in Viatris’ strategic direction and its potential for growth in the biosimilars sector.

Conclusion

Viatris’ decision to sell its stake in Biocon Biologics and reenter the biosimilars market marks a significant strategic shift. By unlocking capital and removing competitive restrictions, the company is positioning itself to capitalize on opportunities in the rapidly evolving pharmaceutical landscape. Investors and industry stakeholders will be closely monitoring how Viatris leverages this move to drive future growth and innovation.